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SUMMARY 
 
Narcolepsy is a chronic sleep-wake disorder characterized by excessive daytime 
sleepiness (EDS) and sudden loss of muscle tone triggered by emotions (cataplexy). Further 
symptoms include sleep paralysis, hypnagogic hallucinations and fragmented night-time 
sleep. Diagnosis of narcolepsy is clinical and supported by three different biological markers: 
first, the electrophysiological documentation of two or more sleep onset REM periods on the 
multiple latency test; second, the genetic predisposition with HLA DQB1*0602 allele 
positivity and third, the loss of the hypothalamic peptide hypocretin (also called orexin).  
As much as several etiological, pathophysiological and clinical characteristics of 
narcolepsy were clarified over the past 15 years, lots of questions remain and newly emerge. 
The majority of them are related to the discovery of the hypocretin system and the hypocretin 
deficiency in narcolepsy. Hypocretins are highly excitatory neuropeptide hormones, produced 
in the perifornical area of the lateral hypothalamus. They have been implicated in 
maintenance of wakefulness, emotional processing, especially reward, energy homeostasis 
and learning.  
In our previous work, we tried to link hypocretin deficiency in narcolepsy to external 
factors, such as traumatic brain injury. We studied manifestations of narcolepsy, which spread 
beyond the classical sleep-wake disorder symptoms, including a specific form of cataplexy, 
time perception and emotional processing, with emphasis on humour, reward and emotional 
learning. Using clinical, electrophysiological and neuroimaging methods, we tried to find the 
functional, metabolic and structural correlates of these manifestations, and link them to 
hypocretin deficiency. We also applied manipulation of sleep pressure in order to study 
homeostatic mechanisms of narcolepsy. 
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1. INTRODUCTION 
 
Narcolepsy with cataplexy (NC) is characterized by excessive daytime sleepiness 
(EDS) and sudden loss of muscle tone, triggered by emotions (cataplexy)1. Additional 
symptoms include hypnagogic hallucinations, sleep paralysis and fragmented night-time 
sleep. NC is a debilitating sleep-wake disorder, affecting between 25 and 50 per 100 000 
people. Diagnosis of NC is clinical, yet a striking association with different biological 
markers has been observed. First, the presence of two sleep onset REM periods  on multiple 
sleep latency test supports the diagnosis of NC2. Second, there is a strong association with the 
HLA system, with the genetic marker HLA DQB1*0602 being found in 98% of patients with 
NC compared to only up to 35% of healthy controls3. Third, a decrease or loss of the 
hypothalamic peptide hypocretin (also called orexin) is found in NC4-6.  
The discovery of the hypocretin system7, 8 and its impairment in NC4 triggered 
extensive studies in human subjects and in animal models. Hypocretins have been implicated 
in maintenance of wakefulness9, emotional processing, especially reward10, 11, energy 
homeostasis12 and learning13. Narcolepsy with cataplexy is more than a sleep-wake disorder 
with manifestations extending beyond sleep-wake impairment.  
NC is associated with hypocretin cell loss, yet the aetiology of this loss remains 
unclear. Because of the strong association with the HLA system autoimmune mechanisms 
have been discussed14, however, neurodegenerative processes might also be involved15. 
External factors, such as traumatic brain injury (TBI) might also play a role, as excessive 
daytime sleepiness belongs to the most common sleep-wake disturbances after TBI16.  
Hypocretin cell loss alludes to hypothalamic dysfunction in NC. Human post-mortem 
studies have shown a drastic reduction of hypocretin peptides4, 17 and hypocretin-producing 
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neurons and axons in the hypothalamus4, 18, 19 as well as signs of gliosis4. These neurons have 
widespread excitatory projections in the brain20 and interact with other neurotransmitter 
systems. An important interplay is the one with the dopaminergic system. Hypocretin 
efferents from the lateral hypothalamus innervate midbrain dopaminergic nuclei, and 
dopamine cell bodies express hypocretin receptors20, 21. Activation of hypocretin receptor-
expressing neurons in the ventral tegmental area (VTA) leads to direct activation of 
mesolimbic dopamine neurons and is probably associated with the development of rewarding 
effects22. Intra-VTA administration of hypocretin increases dopamine levels within the 
prefrontal cortex23. Prefrontal cortex dopaminergic neurotransmission plays an important role 
in a variety of higher-order cognitive and affective processes, including learning under 
appetitive and aversive conditions24, working memory25, and attention26.  
Another important area abundant in hypocretin projections is the amygdala. In canine 
narcolepsy, neurodegeneration and gliosis have been reported not only in the hypothalamus, 
but also in the amygdala15. Different observations suggest the possibility of an involvement of 
the amygdala in cataplexy. For example, electrophysiological studies in narcoleptic dogs 
demonstrated changes in neuronal firing in the amygdala during cataplexy27. The amygdala is 
also strongly activated during REM sleep28 and involved in emotional processing29.  
Pathophysiologically, dysfunctional REM sleep regulation is suggested in NC, 
including a disinhibition of REM sleep (as suggested by the occurrence of sleep onset REM 
periods), the appearance of dissociated REM-like states such as cataplexy (REM atonia during 
wakefulness) and hallucinations (REM mentation during wakefulness). However, NREM 
sleep regulation is also essential in NC as insufficient NREM sleep intensity with rapid 
decline of slow wave activity  and increased sleep fragmentation during the second sleep 
cycle in NC have been reported30.  
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Based on the available evidence, it is plausible to assume an impairment of a number 
of neuronal structures and networks in human narcolepsy, such as hypothalamus, amygdala, 
ventral tegmental area and prefrontal cortex. Knowing the functional involvement of these 
structures, changes in higher cognitive functions (including time perception), and emotional 
processing (including reward, humour and aversive conditioning) can be expected in human 
narcolepsy. Using clinical assessment, different behavioural paradigms, electrophysiological 
and neuroimaging techniques and combining these different methods allows to further explore 
the various manifestations of NC and their morphological substrate.  
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2. AIMS OF THE STUDIES 
 
The overall aim of the presented research was to clarify different etiological, 
pathophysiological and clinical aspects of NC. 
The specific aim of the presented studies can be summarized as follows: 
1. To explore the link between NC and traumatic brain injury (study 1) 
2. To investigate NREM sleep homeostasis using manipulation of sleep pressure (study 2) 
3. To assess a special form of cataplexy, namely cataplexy during sexual intercourse 
(orgasmolepsy) (study 3) 
4. To assess time perception in NC (study 4) 
5. To assess emotional processing in NC and its neural basis (studies 5-7) 
6. To identify metabolic correlates of hypothalamus, amygdala and tegmental dysfunction in 
NC (study 8) 
7. To quantify structural brain changes associated with narcolepsy (study 9). 
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3. MATERIALS AND METHODS 
 
3.1 Clinical assessment 
 
We assessed all NC patients, participating in the nine studies, presented in this work, 
using a detailed clinical interview and different validated questionnaires. Diagnosis was based 
on complaints and symptoms, neurological examination, video-polysomnography and 
multiple sleep latency test. All patients were positive for HLA DQB1*0602. As a part of the 
diagnostic process, cerebrospinal fluid hypocretin measurements were available in the 
majority of the patients.  
We used several questionnaires including the Zurich sleep questionnaire, the Epworth 
sleepiness scale, the Sleep Apnoea Scale of the Sleep Disorders Questionnaire, the Ullanlinna 
Narcolepsy Scale, the Swiss Narcolepsy Scale, and the Stanford Cataplexy Questionnaire. 
The Zurich sleep questionnaire includes 69 questions addressing sleep–wake habits 
and complaints. The answers provide information on symptoms/signs suggestive of sleep 
apnoea, EDS, narcolepsy, different parasomnias, insomnia, and disturbances of the sleep–
wake rhythm. Possible answers include “yes” and “no” or provide a rating on a 5-point scale 
depending on the frequency of occurrence (“almost always”, “often”, “occasionally”, 
“seldom” or “never”).  
Four validated scores are included in the questionnaire. The Epworth sleepiness scale 
is a scale for assessment of subjective EDS based on eight questions on the urge to sleep in 
various life situations31. Each question is rated on a 4-point scale, ranging from 0 to 3 points, 
thus resulting in a maximum sum score of 24 points. A score of 10 or above is considered 
abnormal.  
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The Sleep Apnoea Scale of the Sleep Disorders Questionnaire is a screening instrument for 
obstructive sleep apnoea. It consists of 12 items for sleep-related breathing disorders, and 
includes the well-known risk factors of age and body mass index. Cut-off scores of 32 for 
women and 36 for men (range is 12–60) provide a sensitivity of 85% and a specificity of 72% 
for males and 88% and 81% for females, respectively32. The 11-item Ullanlinna Narcolepsy 
Scale is a widely used screening instrument for narcolepsy33. A cut-off of 14 has been shown 
to have a high sensitivity (100–96%) for patients with NC but specificity is variable (99–
56%)34. The Swiss Narcolepsy Scale is based on five questions; a score <0 had a sensitivity 
and specificity for NC of 96 and 98%, respectively34. The Stanford Cataplexy Questionnaire 
contains 51 items on cataplexy, including questions on cataplexy triggers, localization, 
duration, and frequency of the attacks35.  
In studies 4-9, psychometric assessment was also performed using standard tools, 
including the Beck Anxiety inventory, Beck Depression Inventory and Speilberger State-Trait 
Anxiety Inventory (in studies 5-9). 
In study 1, the subjects who reported TBI, and in study 3, the subjects who reported 
cataplexy during sexual intercourse (orgasmolepsy), were contacted to obtain more details 
about their complaints. 
 Healthy subjects, age and gender matched to our NC patients, served as controls in 
studies 2 and 4-9. Healthy subjects served as controls also in study 3. NC patients were 
compared not only to healthy control subjects but also to patients with EDS of different origin 
in study 3 and to another group of patients with reported hypocretin cell loss, namely patients 
with Parkinson’s disease, in study 4. 
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3.2 Behavioural tests 
 
In studies 4-7 different behavioural paradigms were used: 
 
In study 4, all subjects performed a short time production task, where they had to 
produce an interval of 1, 2 or 5 s. They were asked to press a button on the keyboard when 
they thought the interval of 1, 2 or 5 s had elapsed. Counting was not explicitly prohibited. 
Each target time duration was produced separately. The task consisted of six blocks of 30 
estimations each, with two blocks for each target duration (Fig. 1). The sequence of target 
durations was varied randomly between participants. 
 
Fig. 1: Schematic representation of the task: 
 
Each target duration (1, 2 and 5 s) was estimated separately twice in blocks of 30 estimations. 
The sequence of the target durations was randomly varied between subjects. To test for 
changes in time estimation over the time course of the experiment, the mean duration of the 
first five estimations was compared to the mean duration of the last five estimations in each 
block for each target duration (presented in light grey). 
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In study 5, a humour judgment paradigm was used, combined with functional 
magnetic resonance imaging (fMRI). Minisequences, consisting of a first neutral picture 
followed by a second picture with an either humorous or a neutral new element were 
presented during fMRI assessment (Fig. 2). On each trial, the participants judged whether 
they found the sequence funny or not. 
 
Fig. 2: Stimulus sequence. Each trial consisted of a first neutral picture followed by a second 
picture with a new element which was either neutral or humorous. Subjects judged if the 
sequence was funny or not after the presentation of the second picture. 
 
 
Picture 1, neutral                             Picture 2       Judgement: Y/N 
                                   Humorous or neutral 
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In study 6, an aversive conditioning paradigm was combined with fMRI. On each trial, 
one triangle was displayed at the centre of the screen and the subjects had to decide as quickly 
and as accurately as possible whether the triangle was pointing to the left or to the right. 
Subjects were required to respond on each trial, which allowed us to check whether they paid 
attention to each stimulus and did not fall asleep. Triangles were either blue or yellow in 
colour. One colour (conditioned stimulus) signalled a possible upcoming aversive 
unconditioned stimulus, which was a brief, mildly painful electrical stimulation delivered on 
one finger on half of the conditioned stimulus trials (partial reinforcement conditioning 
paradigm). The other colour was never associated with any other stimulation (nonconditioned 
stimulus). The acquisition phase was followed by extinction phase, where conditioned 
stimulus was not paired with the unconditioned stimulus anymore (Fig. 3). 
 
Fig. 3: Aversive conditioning experimental paradigm: 
 
 
 
 
 
 
 
 
 
 
 
 
Acquisition Extinction 
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In study 7, a game-like task was combined with fMRI. The subjects could win (or 
lose) points if they rapidly pressed on a key while a visual target was briefly shown (Fig. 4). 
During each trial, the subjects were presented with a cue indicating the potential gain (+1 or 
+5 points) or potential loss (-1 or -5 points) associated with that particular trial. After a 
variable delay, the visual target that required a rapid key press was briefly presented on the 
screen. A feedback display, telling the subjects whether they had won or lost, was presented at 
the end of each trial. The paradigm design allowed different comparisons: cue and feedback 
presentation, large and small trials, success and failure, gain and no gain. 
 
Fig. 4: Representation of the task:  
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3.3 Modulation of sleep pressure paradigm, sleep recordings and analysis 
 
In study 2 we used a paradigm which allowed us to modulate sleep pressure.  Baseline 
night-time sleep (23:00-7:00 h), which served also as a screening night, and daytime sleep 
under either higher (no sleep in the previous night) or lower sleep pressure (allowing 4 hours 
of sleep from 23:00-3:00 h in the previous night) was recorded in all participants on non-
consecutive occasions. Partial and total sleep deprivation (SD) were performed in the sleep 
laboratory on two separate nights at least 7 days apart in order to allow full recovery from 
previous SD. The participants were randomly assigned to begin with either partial or total SD. 
All participants arrived in the laboratory at 19:00 h and were kept awake either until 7:00 h 
the next morning (total SD, higher sleep pressure) or were allowed 4 hours of sleep (23:00-
3:00 h, partial SD, lower sleep pressure). Morning recovery sleep was recorded from 7:00 h 
until latest 15:00 h. During baseline nights, video-polysomnography consisted of eight 
channel EEG (F3/A2, F4/A1, C3/A2, C4/A1, P3/A2, P4/A1, O1/A2, O2/A1), left and right 
electrooculography (EOG), submental electromyography (EMG), electrocardiography (ECG), 
respiratory flow (using a nasal cannula) and effort (using Medcare XactTrace respiratory 
inductive plethysmography technology belts), pulse-oximetry and left and right anterior 
tibialis EMG. During morning recovery sleep after total and partial SD in the previous night 
sleep, scoring was based on EEG, EOG, EMG and ECG. All recordings were done on 
Medcare Somnologica Studio. Sleep stages, periodic limb movements and arousals during 
baseline night were scored manually according to international criteria2, 36, 37. Sleep onset was 
defined as the first epoch of either NREM 2 or REM sleep. Cyclic alternating pattern  
parameters were scored and analysed for each subject38.  
Cyclic alternating pattern is a way to describe the arousability state during NREM sleep. 
Different subtypes have been defined: subtypes A1 – slow frequency high-voltage EEG 
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patterns (sequences of K-complexes and delta-bursts), subtypes A2 – rapid low-amplitude 
EEG patterns preceded by or mixed with slow high voltage waves and subtypes A3 – phases 
with fast low-voltage EEG patterns 38. The A1 subtypes are abundant during the build-up of 
deep NREM sleep and play a role in NREM sleep maintenance while subtypes A2 and A3 
indicate NREM sleep disruption39, 40. Additionally A2 and A3 subtypes occur more often 
before the onset of and during REM sleep, thus suggesting an association with REM-on 
mechanisms, active during the last part of a NREM sleep episode and during REM sleep40. 
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3.4 Neuroimaging 
For studies 5-7, whole-brain event-related fMRI data were acquired on a Philips Intera 
3.0-Tesla whole-body system (Philips Medical Systems, Best, NL). The scanning parameters 
were optimized during pilot testing to minimize susceptibility-related signal losses in 
orbitofrontal cortex and inferior temporal regions. Processing and statistical analyses of 
imaging data were performed with SPM2 (www.fil.ion.ucl.ac.uk). 
 
In study 8, ¹H-MRS was performed on a 3T Philips Achieva whole body magnetic 
resonance scanner. Single-voxel proton magnetic resonance spectra were acquired from 
hypothalamus (a volume of interest [VOI] of 1 cm³ was selected to include bilateral grey 
matter), both amygdala (VOI of 1 cm³), and the pontomesencephalic junction (VOI of 1.9 
cm³). Water-suppressed proton MR spectra were acquired using a PRESS single-voxel 
localization sequence. Second-order shimming (3T Philips Achieva) was used. Acquisition 
time for each VOI was 19 minutes. Levels of N-acetylaspartate (NAA), N-
acetylaspartateglutamate (NAAG), NAA+NAAG (total NAA), myoInositol (mI), 
creatinephosphocreatine (Cr), and choline were analysed by fitting a linear combination of a 
basis set of metabolite model spectra to the data (LCModel) 41. The metabolite concentrations 
were expressed as ratios relative to Cr peak.  
As neuronal cell loss and gliosis in different regions of interest in NC have been 
described, we focused on NAA, a marker of neuronal integrity and on mI, a glial marker 
 
In study 9 cerebral MRI was acquired with a T1-weighted 3D volumetric pulse 
sequence using a Philips Achieva 3T scanner as a series of 180 contiguous axial slices, with a 
voxel size of 0.86 x 0.86 x 0.76 mm. Cortical reconstruction and volumetric segmentation 
were performed using published algorithms included in the FreeSurfer package (Martinos 
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Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, USA). 
Regional cortical volumes, cortical thickness and gyrification were computed. 
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4. RESULTS 
In study 1 we found a much higher frequency of TBI prior to the occurrence of NC 
(19%) in comparison to the general population (about 1%)42.  
 
Study 2 showed significantly lower cyclic alternating pattern (CAP) rate, CAP index, 
CAP time, number of CAP cycles, A1 index and number of A1 cycles in comparison to 
healthy controls. A2 and A3 subtypes were not significantly different between patients and 
controls. CAP parameters decreased significantly after partial and total sleep deprivation. 
Most of these changes followed a similar pattern after partial and total SD in patients and 
controls (Fig. 5).   
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Fig. 5: Graphic representation of the dynamics in CAP parameters at baseline and after partial 
and total sleep deprivation during morning recovery sleep.  
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In study 3, orgasmolepsy was found in 10% of our NC patients, yet one patient with 
excessive daytime sleepiness due to behaviourally induced insufficient sleep syndrome also 
reported the symptom. All NC patients who experienced orgasmolepsy had frequent partial 
cataplexy and severe daytime sleepiness. In the female NC patients, orgasmolepsy occurred 
by each sexual intercourse, and the male patient reported orgasmolepsy only when in a 
relationship involving emotional commitment and trust. In the patient with behaviourally 
induced insufficient sleep syndrome and orgasmolepsy, cataplexy-like symptoms involved 
unilaterally upper or lower limbs in association with negative emotions or sports activities. 
 
In study 4, NC patients tended to overproduce all time target durations, compared to 
patients with Parkinson’s disease (PD) and healthy control subjects (Fig. 6).  
 
Fig. 6: Mean time productions for each target duration in each group, mean ± SEM 
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The temporal accuracy index was computed by taking the ratio of the duration produced to the 
target duration (1, 2 or 5 s). Because target duration is considered as the reference, a ratio <1 
corresponds to shorter productions and a ratio >1 corresponds to longer productions than the 
target duration. Narcolepsy patients tended to have higher accuracy index (pointing to time 
overproduction) in comparison to controls and PD patients (Fig.7).  
 
Fig. 7: Accuracy of time production/estimation 
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NC patients also showed higher absolute variability than controls and PD patients (Fig. 7 and 
Fig. 8).  
Fig. 7: Absolute variability of time production/estimation for each group and each target 
duration, mean ± SEM. 
 
Fig. 8: Relative variability (coefficient of variability) of time production/estimation for each 
group and each target duration, mean ± SEM. 
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The analysis of the temporal course of time estimation showed more pronounced 
overproduction of each target duration at the end of each trial in NC patients, whereas 
performance was more or less stable in controls and PD patients (Fig. 9). 
 
Fig. 9: Dynamics of accuracy of time estimation, mean ± SEM in the first and last five trials 
in each group of each target duration: a – for 1s, b – for 2s and c – for 5s. 
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Studies 5-7 assessed different aspects of emotional processing.  
Humorous pictures in study 5 elicited reduced hypothalamic response (Fig. 10) together with 
enhanced amygdala (Fig. 10), left insula and nucleus accumbens (Fig. 12) response in NC. 
 
Fig. 10: Increased response to humour in right hypothalamus in controls compared to NC 
patients: 
 
 
Fig. 11: Increased amygdala response to humour in NC patients compared to controls. 
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Fig 12: Increased fMRI signal in left insula and nucleus accumbens in NC patients. 
 
 
In study 6, NC patients had no enhancement of amygdala response to conditioned 
stimuli and no increase in functional coupling between the amygdala and medial prefrontal 
cortex in comparison to control subjects (Fig. 13). 
 
Fig. 13: Activation of amygdala in control subjects. 
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Study 7 showed that activity in the dopaminergic VTA was not modulated in NC patients 
during high reward expectancy (Fig. 14), and that ventral striatum activity was reduced during 
winning. The patients showed abnormal activity increases in the amygdala and in dorsal 
striatum for positive outcomes (Fig. 16). In addition, activity in the nucleus accumbens and 
the ventral-medial prefrontal cortex correlated with disease duration.  
 
Fig. 14: VTA activation during the presentation of high-incentive cues in controls compared 
to NC patients. 
 
 
Fig. 15: Increased amygdala activity for positive outcomes in NC patients in comparison to 
controls. 
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Having demonstrated abnormal activation in hypothalamus and amygdala in Studies 5-
7, we also showed metabolic changes in these regions in study 8, namely myoInositol (mI)/Cr 
was significantly lower in the right amygdala of NC patients, compared to controls (Fig. 16). 
 
Fig. 16: A: metabolite concentration ratios in hypothalamus; B: metabolite concentration 
ratios in the pontomesencephalic junction; C: metabolite concentration ratios in the right 
amygdala; D: metabolite concentration ratios in the left amygdala. 
 
 
Significant negative correlations were found only in the patients group between (total 
NAA)/Cr in hypothalamus and ml/Cr in the right amygdala, between ml/Cr in hypothalamus 
and (total NAA)/Cr in the right amygdala and between ml/Cr in the left amygdala and total 
NAA)/Cr in the pontomesencephalic junction. 
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In study 9, after showing functional and metabolic brain changes in NC, we 
demonstrated structural brain changes such as decreased cortical volume in the left 
paracentral lobule and increased cortical volume in the left caudal part of the middle frontal 
gyrus (Fig. 17). Cortical thickness in prefrontal areas, especially in the right orbitofrontal 
cortex, was associated with symptom severity in NC. Further, we observed several clusters of 
cortical thinning in patients with childhood or adolescent onset of NC compared with patients 
with adult disease onset. 
 
Fig. 17: Increased volume in the caudal part of the left middle frontal gyrus (in blue) and 
decreased volume in the left paracentral gyrus (in red) in NC patients in comparison to 
controls. 
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5. DISCUSSION AND OUTLOOK 
 
In this work, we attempted to elucidate various etiological, pathophysiological and 
clinical aspects of NC, using a multimodal approach, comprising of questionnaires, 
behavioural paradigms, electrophysiological recordings and different neuroimaging methods.  
We confirmed that NC is more than just a sleep-wake disorder and that its manifestations 
spread widely beyond the classical sleep-wake complaints. 
With study 1 we attempted to clarify the link between TBI and NC. Our previous 
findings of deficient hypocretin signalling after TBI43, the higher prevalence of TBI in our NC 
population than in the general population42 and the short intervals between TBI and onset of 
NC in most of our patients suggest that TBI may cause a symptomatic loss of hypocretin 
neurons in susceptible patients, which may lead to the clinical picture of NC. Thus external 
factors together with genetic predisposition seem to be essential for the development of NC. 
In study 2 we examined NC pathophysiology, in particular NREM homeostasis. We 
used manipulation of sleep pressure and cyclic alternating pattern analysis. The decrease of 
A1 subtypes in NC during baseline sleep, which are important for the build-up of deep NREM 
sleep, indicate insufficient NREM sleep intensity in NC. Conversely, A2 and A3 subtypes, 
which are linked to REM-on mechanisms, did not differ between NC patients and controls, 
thus suggesting that REM-on mechanisms are operational in NC. The baseline differences 
between NC patients and controls persisted after total and partial SD and followed a similar 
pattern, indicating similar homeostatic NREM regulation in NC patients and healthy controls. 
Having worked on etiological and pathophysiological mechanisms of NC, in studies 3-
7 we were interested in symptoms and behavioural features of NC which expand beyond the 
well-known classical clinical characteristics. We also attempted to at least partially link our 
findings to hypocretin deficiency. In study 3 we postulated that orgasmolepsy is a distinct 
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feature of NC, which however, is also reported by patients with other sleep-wake disorders 
and excessive daytime sleepiness. We hypothesized that insufficient arousal may favour the 
occurrence of cataplexy and cataplexy-like symptoms, including orgasmolepsy. Considering 
the dense hypocretinergic projections to areas known to be part of reward networks20, 
including the ones involved in sexual arousal and orgasm, we assumed that hypocretin 
deficiency and reward dysregulation in NC may further facilitate orgasmolepsy. 
In study 4 we explored time perception in NC. We expected deficits in accuracy and 
variability of responses in NC patients as overproduction of target durations in the light of 
possible prefrontal dysfunction and attention deficits. Indeed we found overproduction and 
higher variability of all time durations in NC, which indicates impaired short interval timing 
in the seconds range. The time-course of accuracy and variability of time production within 
sessions indicate an attention-related mechanism of impaired interval timing. As intact 
prefrontal cortex is critical for interval timing44, and the prefrontal cortex receives dense 
hypocretin projections hypocretin mediated dopaminergic ventral tegmental area projections, 
a role of hypocretin in time processing can be suggested. 
Studies 5-7 focused on different aspects of emotional processing and their link to brain 
function. The findings of increased amygdala activity together with reduced medial prefrontal 
and hypothalamic activity during humour processing in Study 5 suggest that the hypothalamus 
might have modulatory influence on amygdala activity during positive emotions, possibly via 
direct projections from hypothalamic hypocretin neurons to the amygdaloid complex20, 21. 
Reduced hypothalamic activation and exaggerated amygdala response to humour could be due 
to loss of hypothalamic hypocretin neurons in NC. Hypocretin has been shown to influence 
affective responses through projections to the VTA22. In turn, intra-VTA administration of 
hypocretin increases dopamine levels within the prefrontal cortex23. Activity in prefrontal 
cortex might suppress amygdala responses45. The reduced hypothalamic and prefrontal 
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activity and the increased amygdala activation in NC patients could be due to a dysfunction of 
hypocretin/dopamine-mediated pathways that usually inhibit amygdala activity. This also 
could lead to an abnormally high amygdala response to positive emotions in NC. Narcolepsy 
patients also had elevated fMRI responses to humour in the left nucleus accumbens, a key 
component of the mesolimbic reward system known to be involved in humour processing46.  
 Another aspect of emotional processing in NC was assessed in study 6. During 
aversive conditioning there was no increase in amygdala response to the conditioned stimulus 
alone, suggesting a selective impairment in emotional learning. Thus study 6 provided further 
evidence for amygdala dysfunction in NC.  
Study 7 also studied the emotional brain in NC, focusing on reward processing. 
Hypocretin has been implicated in reward processing in animal studies. This was the first 
study to assess reward-related brain responses in human NC. It provided proof for the role of 
hypocretin in reward processing in the human brain. The lack of VTA activation in NC 
patients might be explained with deficient hypocretinergic stimulation of this region. 
Additionally brain responses to reward in NC were affected in regions receiving dense 
hypocretinergic projections and/or those modulated by dopaminergic inputs from the VTA, 
such as nucleus accumbens and the prefrontal cortex.  
In Studies 8 and 9 we were looking for metabolic and structural correlates of the above 
demonstrated functional brain dysfunction. Indeed study 8 showed metabolic changes in the 
right amygdala and also suggested hypothalamo-amygdala dysfunction on metabolic level in 
NC. Study 9 then found different volumetric changes, including areas within the prefrontal 
cortex, rich in hypocretinergic projections, as already mentioned above. Moreover cortical 
thickness in two prefrontal regions, especially in the right orbitofrontal cortex, was associated 
with symptom severity in NC. The right orbitofrontal cortex is densely connected to the VTA 
and amygdala, which in turn were shown to be dysfunctional in studies 5-7 in the same 
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sample of patients. The location of the changes in the right orbitofrontal cortex is not a 
coincidence and can be explained in the context of altered function of the reward circuitry in 
NC patients. The abnormal activity of the VTA, together with the altered orbitofrontal cortex, 
could impair the reinforcing effect of positive reward on behaviour in NC patients. 
 
Narcolepsy with cataplexy is a fascinating disease with complex aetiology, 
pathophysiology and clinics. The clinical manifestations of NC spread beyond sleep-wake 
disturbances and include impaired time perception, emotional processing, with an emphasis 
on humour, reward and emotional learning.  We characterized some of the functional, 
metabolic and structural brain substrates of these manifestations.  
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6. ABBREVIATIONS 
CAP   - cyclic alternating pattern 
Cr   - creatinephosphocreatine  
ECG   - electrocardiography 
EDS  - excessive daytime sleepiness 
EEG  - electroencephalography 
EMG  - electromyography 
EOG  - electrooculography 
fMRI  - functional magnetic resonance imagimg 
HLA  - human leucocyte antigen  
mI  - myoInositol 
NAA  - N-acetylaspartate   
NAAG - N-acetylaspartateglutamate 
NC  - narcolepsy with cataplexy 
NREM - non-rapid eye movement sleep 
PD  - Parkinson’s disease 
REM  - rapid eye movement sleep 
SD  - sleep deprivation 
SEM  - standard error of the mean 
SPM  - statistical parametric mapping 
TBI  - traumatic brain injury 
total NAA - NAA+NAAG 
VOI  - volume of interest 
VTA  - ventral tegmental area 
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